10-KPeriod: FY2014

BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2014

Filed February 25, 2015For Securities:BSX

Summary

Boston Scientific Corporation's (BSX) 2014 10-K filing highlights a year of revenue growth and strategic acquisitions, alongside significant litigation charges. Net sales increased by 3% to $7.38 billion, driven by strong performance in Interventional Cardiology, Electrophysiology, Endoscopy, and Peripheral Interventions. However, the company reported a net loss of $119 million, largely impacted by a $600 million settlement with Johnson & Johnson related to the Guidant acquisition. Excluding these and other charges, adjusted net income was $1.13 billion, or $0.84 per share. The company continued to execute its five strategic imperatives: strengthening execution to grow share, expanding into high-growth adjacencies, driving global expansion, funding growth initiatives, and developing key capabilities. Key acquisitions during the year included the Interventional Division of Bayer AG and IoGyn, Inc., aimed at strengthening the company's product portfolio and market position. BSX emphasizes its commitment to innovation, investing $817 million in R&D. The company also returned value to shareholders through $125 million in share repurchases. Despite ongoing healthcare policy changes and pricing pressures, Boston Scientific maintains an optimistic outlook, focusing on its diverse product portfolio and strategic growth opportunities.

Financial Highlights

53 data points
Beta

Revenue

$7.46B

69.3% Gross Margin

Net Income

-$119.00M

-1.6% Net Margin

EPS (Diluted)

$-0.09

Total Assets

$17.02B

Cash & Equivalents

$587.00M

Free Cash Flow

$1.01B

Financial Statements
Beta
Revenue$7.46B
Cost of Revenue$2.21B
Gross Profit$5.17B
SG&A Expenses$2.90B
Operating Expenses$5.47B
Operating Income-$301.00M
Interest Expense$216.00M
Net Income-$119.00M
EPS (Basic)$-0.09
EPS (Diluted)$-0.09
Shares Outstanding (Basic)1.32B
Shares Outstanding (Diluted)1.32B

Key Highlights

  • 1Net sales increased by 3% to $7.38 billion in 2014, driven by growth across key business segments.
  • 2Reported a net loss of $119 million, primarily due to a $600 million litigation settlement with Johnson & Johnson.
  • 3Excluding certain charges, adjusted net income was $1.13 billion, or $0.84 per share.
  • 4Completed strategic acquisitions of Bayer AG's Interventional Division and IoGyn, Inc. to enhance product offerings.
  • 5Invested $817 million in Research and Development (R&D) to fuel future innovation.
  • 6Returned $125 million to shareholders through share repurchases.
  • 7Maintains investment-grade credit ratings with all three major credit-rating agencies.

Frequently Asked Questions

In 2014, Boston Scientific reported a 3% increase in net sales to $7.38 billion, demonstrating revenue growth. However, the company recorded a net loss of $119 million, significantly influenced by a $600 million litigation settlement with Johnson & Johnson. When excluding these significant charges and other non-recurring items, adjusted net income was $1.13 billion.

Revenue growth was primarily driven by strong performance in the Interventional Cardiology segment ($2.057 billion in sales), Cardiac Rhythm Management ($1.912 billion), Endoscopy ($1.323 billion), and Peripheral Interventions ($850 million). Constant currency growth was notable in Interventional Cardiology (+5%), Electrophysiology (+48%), Endoscopy (+5%), and Peripheral Interventions (+7%).

The company faces intense competition, rapid technological changes in the medical device industry, and pricing pressures. Risks also include the successful integration of acquired businesses, management of debt levels, potential goodwill and intangible asset impairment charges, changes in healthcare policies and reimbursement rates, and regulatory compliance. Significant litigation and intellectual property disputes are also highlighted as key risks.

Boston Scientific maintained total debt of $4.262 billion as of December 31, 2014. The company had $587 million in cash and cash equivalents and access to a $2.0 billion revolving credit facility. It held investment-grade ratings from all three major credit rating agencies, reflecting its financial strategy and performance.